

Applicants: Kung, *et al.*
U.S.S.N.: 10/590,672

Amendments to the Claims:

This listing of the claims replaces all prior versions of the claims in the application:

Listing of the claims:

1. (Currently amended) A method of inhibiting ~~tumor~~ multiple myeloma cell growth in a subject comprising administering to said subject a cytotoxic or a chemotherapeutic agent and a composition comprising an insulin-like growth factor receptor-1 (IGF-1R) inhibitor, wherein said IGF-1R inhibitor is ADW-742 or NVP-AEW541.
2. (Original) The method of claim 1, wherein said composition is administered concomitantly with said agent.
3. (Original) The method of claim 1, wherein said composition is administered within 48 hours after said agent.
4. (Original) The method of claim 1, wherein said composition is administered within 24 hours after said agent.
5. (Original) The method of claim 1, wherein said composition is administered within 12 hours after said agent.
6. (Original) The method of claim 1, wherein said composition is administered within 3-12 hours after said agent.
7. (Original) The method of claim 1, wherein said composition is administered over a preselected period of time.
8. (Currently amended) The method of claim [[2]]7, wherein said preselected period of time is about 1 to 2 days.
9. (Original) The method of claim 1, wherein the dose of said agent is sub-therapeutic.

Applicants: Kung, *et al.*
U.S.S.N.: 10/590,672

10. (Original) The method of claim 1, wherein the dose of said IGF-1R inhibitor is sub-therapeutic.

11. (Original) The method of claim 1, wherein the dose of said IGF-1R inhibitor is in an amount sufficient to cause hyperglycemia, ketosis or glucosuria.

12.-16. (Canceled)

17. (Original) The method of claim 1, wherein said chemotherapeutic agent is doxorubicin, melphalan or dexamethasone.

18.-59. (Canceled)

60. (New) The method of claim 1, wherein said IGF-1R inhibitor is ADW-742.

61. (New) The method of claim 1, wherein said IGF-1R inhibitor is NVP-AEW541.